GSK plc
10% Owner
GSK plc10% Owner
GSK plc insider trades: Wave Life Sciences (WVE) stock buys and sales
10% Owner, Wave Life Sciences Last trade Dec 11, 2025 82 Form 4 filings
$0
Sold, last 12 months
0 sales
$27.9M
Bought, last 12 months
1 buy
66
Open-market trades
since 2005
34
Companies
last trade 2025
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where GSK plc reports to the SEC
WVEWave Life Sciences
10% Owner · last filing Dec 15, 2025
+$66.8M
CVRXCVRx
10% Owner · last filing Jul 6, 2021
+$5.0M
LYELLyell Immunopharma
10% Owner · last filing Jun 23, 2021
No market trades
INVAInnoviva
10% Owner · last filing May 24, 2021
-$392.1M
DBTXDecibel Therapeutics
Director · last filing Feb 19, 2021
+$2.7M
GNCAGenocea Biosciences
10% Owner · last filing Jul 30, 2020
+$11.1M
and 28 more companies
Open-market buys and sales
66 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Dec 11, 2025 | WVE | ↑ Buy | 1,470,000 | $19.00 | $27.9M | By Corporation | Dec 15, 2025 (4d) |
| Sep 27, 2024 | WVE | ↑ Buy | 2,791,930 | $8.00 | $22.3M | By Corporation | Oct 1, 2024 (4d) |
| Dec 7, 2023 | WVE | ↑ Buy | 3,300,000 | $5.00 | $16.5M | By Corporation | Jan 30, 2024 (54d) |
| Jul 2, 2021 | CVRX | ↑ Buy | 275,000 | $18.00 | $5.0M | Indirect | Jul 6, 2021 (4d) |
| May 20, 2021 | INVA | ↓ Sell | 32,005,260 | $12.25 | $392.1M | Indirect | May 24, 2021 (4d) |
| Feb 17, 2021 | DBTX | ↑ Buy | 150,000 | $18.00 | $2.7M | Indirect | Feb 19, 2021 (2d) |
| Jul 24, 2020 | GNCA | ↑ Buy | 1,260,504 | $2.25 | $2.8M | Indirect | Jul 30, 2020 (6d) |
| Jul 21, 2020 | PAND | ↑ Buy | 361,111 | $18.00 | $6.5M | Indirect | Jul 22, 2020 (1d) |
| Jul 15, 2020 | BCYC | ↓ Sell | 4,744 | $19.36 | $92K | Indirect | Sep 18, 2020 (65d) |
| Jul 14, 2020 | NKTX | ↑ Buy | 833,333 | $18.00 | $15.0M | Indirect | Jul 16, 2020 (2d) |
| May 21, 2020 | TPTX | ↑ Buy | 83,333 | $60.00 | $5.0M | Indirect | May 26, 2020 (5d) |
| May 20, 2020 | PGNY | ↓ Sell | 4,000,000 | $25.75 | $103.0M | Indirect | May 21, 2020 (1d) |
| Oct 18, 2019 | PRNB | ↑ Buy | 357,142 | $28.00 | $10.0M | Indirect | Oct 22, 2019 (4d) |
| Sep 10, 2019 | TPTX | ↑ Buy | 177,777 | $45.00 | $8.0M | Indirect | Sep 12, 2019 (2d) |
| Jul 1, 2019 | MORF | ↑ Buy | 333,333 | $15.00 | $5.0M | Indirect | Jul 2, 2019 (1d) |
| Jun 24, 2019 | GNCA | ↑ Buy | 1,857,142 | $3.50 | $6.5M | See Footenote | Jun 26, 2019 (2d) |
| May 28, 2019 | BCYC | ↑ Buy | 385,714 | $14.00 | $5.4M | Indirect | May 30, 2019 (2d) |
| Apr 22, 2019 | TPTX | ↑ Buy | 325,000 | $18.00 | $5.8M | Indirect | Apr 24, 2019 (2d) |
| Oct 16, 2018 | CCXI | ↓ Sell | 7,343,492 | $11.69 | $85.8M | Indirect | Oct 18, 2018 (2d) |
| Sep 18, 2018 | PRNB | ↑ Buy | 270,000 | $17.00 | $4.6M | Indirect | Sep 20, 2018 (2d) |
| Jul 30, 2018 | LQDA | ↑ Buy | 148,818 | $11.00 | $1.6M | See explanation of responses | Aug 1, 2018 (2d) |
| Jul 17, 2018 | SPRO | ↑ Buy | 80,000 | $12.50 | $1.0M | By S.R. One, Limited | Jul 17, 2018 (0d) |
| Jul 2, 2018 | TBIO | ↑ Buy | 269,230 | $13.00 | $3.5M | Indirect | Jul 3, 2018 (1d) |
| Nov 6, 2017 | SPRO | ↑ Buy | 428,571 | $14.00 | $6.0M | Indirect | Nov 7, 2017 (1d) |
| Mar 27, 2017 | HTGM | ↓ Sell | 300,000 | $10.15 | $3.0M | By S.R. One, Limited | Mar 29, 2017 (2d) |
| Oct 24, 2016 | CRSP | ↑ Buy | 66,500 | $14.00 | $931K | See explanation of responses | Oct 26, 2016 (2d) |
| Mar 14, 2016 | TBPH | ↑ Buy | 1,301,015 | $23027965.50 | $29959.73B | By Corporation | Mar 15, 2016 (1d) |
| Oct 7, 2015 | TBPH | ↑ Buy | 44,574 | $607543.62 | $27.08B | By Corporation | Oct 7, 2015 (0d) |
| Aug 7, 2015 | THRX | ↑ Buy | 245,828 | $3485841.04 | $856.92B | By Corporation | Aug 7, 2015 (0d) |
| May 11, 2015 | HTGM | ↑ Buy | 365,106 | $14.00 | $5.1M | By S.R. One, Limited | May 13, 2015 (2d) |
| May 11, 2015 | THRX | ↑ Buy | 85,579 | $1369264.00 | $117.18B | By Corporation | May 11, 2015 (0d) |
| Mar 2, 2015 | THRX | ↑ Buy | 92,674 | $1673692.44 | $155.11B | By Corporation | Mar 2, 2015 (0d) |
| Feb 23, 2015 | AGTC | ↓ Sell | 503,150 | $22.00 | $11.1M | By S.R. One Limited | Feb 24, 2015 (1d) |
| Dec 18, 2014 | AGTC | ↓ Sell | 50,000 | $21.14 | $1.1M | By S.R. One Limited | Feb 12, 2015 (56d) |
| Nov 4, 2014 | THRX | ↑ Buy | 832,456 | $12786524.16 | $10644.22B | By Corporation | Nov 4, 2014 (0d) |
| Oct 27, 2014 | FOLD | ↓ Sell | 11,315,825 | $5.29 | $59.9M | By Corporation | Oct 28, 2014 (1d) |
| Aug 11, 2014 | THRX | ↑ Buy | 172,651 | $3912271.66 | $675.46B | By Corporation | Aug 11, 2014 (0d) |
| May 9, 2014 | THRX | ↑ Buy | 317,770 | $8544835.30 | $2715.29B | By Corporation | May 13, 2014 (4d) |
| Apr 1, 2014 | AGTC | ↑ Buy | 103,762 | $12.00 | $1.2M | By S.R. One Limited | Apr 2, 2014 (1d) |
| Feb 19, 2014 | CNCE | ↑ Buy | 35,000 | $14.00 | $490K | By S.R. One Limited | Feb 20, 2014 (1d) |
| Feb 11, 2014 | THRX | ↑ Buy | 342,229 | $12850698.95 | $4397.88B | By Corporation | Feb 13, 2014 (2d) |
| Feb 10, 2014 | GNCA | ↑ Buy | 143,773 | $12.00 | $1.7M | Indirect | Feb 12, 2014 (2d) |
| Nov 20, 2013 | FOLD | ↑ Buy | 1,500,000 | $2.00 | $3.0M | By Corporation | Nov 22, 2013 (2d) |
| Oct 29, 2013 | THRX | ↑ Buy | 130,473 | $4913613.18 | $641.09B | By Corporation | Oct 29, 2013 (0d) |
| Jul 30, 2013 | THRX | ↑ Buy | 3,064,407 | $111850855.50 | $342756.54B | By Corporation | Aug 1, 2013 (2d) |
| Apr 30, 2013 | THRX | ↑ Buy | 193,563 | $6699215.43 | $1296.72B | By Corporation | Apr 30, 2013 (0d) |
| Feb 15, 2013 | THRX | ↑ Buy | 116,527 | $2567089.81 | $299.14B | By Corporation | Feb 20, 2013 (5d) |
| Nov 2, 2012 | THRX | ↑ Buy | 280,348 | $6265777.80 | $1756.60B | By Corporation | Nov 5, 2012 (3d) |
| Aug 3, 2012 | THRX | ↑ Buy | 316,334 | $28.21 | $8.9M | By Corporation | Aug 7, 2012 (4d) |
| Aug 2, 2012 | HGSI | ↑ Buy | 68,332,901 | $14.25 | $973.7M | See Explanation of Responses | Aug 3, 2012 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other WVE insiders
Open-market trades in the last 12 months
Adrian Rawcliffe
Insider
3 sales
Aug 12, 2026
Aik Na Tan
Insider
2 sales
Aug 11, 2026
Heidi L Wagner
Insider
2 sales
Aug 11, 2026
Ken Takanashi
Insider
1 sale
Aug 11, 2026
Chris Francis
See Remarks
4 sales
Feb 26, 2026
Paul Bolno
President and CEO
1 sale
Feb 9, 2026
Chandra Vargeese
See Remarks
1 sale
Feb 9, 2026
Kyle Moran
Chief Financial Officer
2 sales
Feb 9, 2026
About GSK plc's insider trades
GSK plc is a 10% owner of Wave Life Sciences (WVE). Since Jul 12, 2005, it has reported 55 open-market purchases worth $396300.86B and 11 sales worth $2.63B on SEC Form 4. In the last 12 months: 1 buy ($27.9M).
Its filings also include conversions (23 filings), other transactions (11 filings), grants and awards (6 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every WVE insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.